A biosurfactant compound produced by a bacterial isolate from burned soils, offering altered surface-active behavior and biological efficacy compared to standard rhamnolipids. Potential applications span antimicrobial formulations, agriculture, and bioremediation.
This offering centers on an unusual rhamnolipid derivative isolated from a bacterial strain found in burned soils. Rhamnolipids are well-characteried biosurfactants—molecules produced by microorganisms that reduce surface tension—with established antifungal properties, particularly against zoospores of plant pathogens. This derivative is hypothesized to retain or enhance antimicrobial activity while exhibiting altered surface-active properties, which could translate into improved performance in formulations where wetting, emulsification, or dispersion is critical. The compound represents a differentiated biological alternative to synthetic surfactants and conventional antimicrobial agents, with potential relevance across agricultural, industrial, and pharmaceutical sectors.
This research is at an early discovery stage. The compound has been identified from a bacterial isolate, and the hypothesis regarding its altered surface-active and biological properties remains to be validated. Further characterization, fermentation optimization, and efficacy testing are needed before commercial or applied deployment can be pursued.
UC Berkeley is a comprehensive public research university of global scale, known for cross‑disciplinary inquiry and a high‑intensity research culture. Industry engages on campus through shared user facilities, project‑based collaborations, and embedded innovation spaces, with proximity to a U.S. Department of Energy national laboratory enabling joint programs and access to specialized instrumentation. Its Bay Area location connects partners to deep talent pipelines and a dense startup ecosystem, enabling rapid prototyping and iteration alongside regional suppliers and investors. Research is supported by competitive federal funding from agencies such as the National Science Foundation, Department of Energy, National Institutes of Health, and DARPA. A dedicated technology transfer office streamlines IP, sponsored research, material transfer agreements, and startup formation, complemented by accelerators and proof‑of‑concept resources.